Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Chairperson and CEO Martine A. Rothblatt reported vesting and settlement of restricted stock units rather than open-market trades. On March 15, 2026, she exercised and converted a total of 69,579 restricted stock units into the same number of common shares on a one-for-one basis.
To cover tax obligations associated with these vestings, 29,196 common shares were withheld by United Therapeutics at $536.12 per share, a non-market tax-withholding disposition. After these transactions, Rothblatt directly held 40,513 shares of common stock, and the filing also shows additional indirect holdings through her spouse and various family trusts.
United Therapeutics director Jan Malcolm reported an open-market sale of company stock. On March 17, 2026, Malcolm sold 45 shares of Common Stock at an average price of $533.51 per share, and now directly holds 125 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Malcolm entered into on September 11, 2025, indicating the transaction was scheduled in advance rather than timed discretionarily.
UTHR files a Form 144 reporting the proposed sale of 45 shares of Common Stock (restricted stock) by an issuer-affiliated holder.
The filing lists multiple recent dispositions by the same holder: 50 shares sold on 03/03/2026 for $25,460.00, and prior 50-share sales on 02/17/2026, 02/03/2026, 01/20/2026, 01/06/2026, and 12/23/2025 with reported gross proceeds shown for each sale. The transactions are reported under Rule 144 notice requirements.
UTHR filed Form 144 reporting sale transactions by Judy Olian. The filing lists two sales of Common shares: 03/02/2026 (200 shares, $101,910.00) and 03/09/2026 (200 shares, $102,000.00). The securities are listed as Restricted Stock with an original grant date of 06/26/2021.
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of company stock. On March 16, 2026, she sold 200 shares of Common Stock at an average price of $535.44 per share in a sale classified as an open-market transaction.
After this sale, she directly holds 4,445 shares of UNITED THERAPEUTICS Common Stock. According to a footnote, this transaction was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and on the same date sold 9,500 shares in open-market trades at weighted average prices between $535.43 and $542.04. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the transactions, she holds 7,150 shares directly and additional indirect holdings through her spouse and family trusts totaling several hundred thousand shares.
United Therapeutics Corp Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On March 12, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
That same day and on March 16, 2026, she completed open-market sales totaling 9,500 common shares at weighted average prices generally between $531.94 and $544.80. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Following these trades, Rothblatt holds 8,414 shares of common stock directly. She also has indirect interests, including 166 shares held by her spouse and shares held in various family trusts, such as 324,518 shares in one trust where family members are beneficiaries.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options covering 9,500 shares of common stock at an exercise price of $146.03 per share and acquired the same number of shares. On the same March 11, 2026, she sold 9,500 common shares in multiple open‑market transactions at prices ranging from $531.90 to $544.94, leaving 130 shares held directly.
The options exercised were originally granted on March 15, 2020 and were scheduled to expire on March 15, 2027. The filing also shows additional indirect holdings, including shares held by a spouse and in several family trusts, such as 324,518 and 258,117 shares reported as held by trusts. All option exercises and related sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is set to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold 9,500 shares in multiple open-market trades at prices generally between about $530 and $548 per share. These transactions on March 10, 2026 were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is designed to execute trades automatically over time. Following the sales, she holds 130 shares directly and also has substantial indirect holdings through family trusts, including 324,518 shares held by a trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On March 9, 2026, she exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares.
That same day, she sold 9,500 shares of common stock in a series of open-market trades, including 200 shares at $500.05 per share and 80 shares at $529.83 per share. After these trades, she held 130 shares directly, and also reported additional indirect holdings through her spouse and several family trusts.
The footnotes state that this option exercise and sale of resulting shares were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.